We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$249M
AUM Growth
-$35.6M
Cap. Flow
-$380M
Cap. Flow %
-152.85%
Top 10 Hldgs %
65.95%
Holding
50
New
11
Increased
8
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$15.7M
2
VOR icon
Vor Biopharma
VOR
+$9.87M
3
CLDX icon
Celldex Therapeutics
CLDX
+$9M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$7.43M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.17M

Top Sells

Rank Stock Value
1
ATYR
aTyr Pharma
ATYR
+$13.6M
2
CYTK icon
Cytokinetics
CYTK
+$12.4M
3
CGON icon
CG Oncology
CGON
+$11.3M
4
REPL icon
Replimune Group
REPL
+$10.8M
5
DFTX
Definium Therapeutics
DFTX
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LPCN icon
26
Lipocine
LPCN
$17.7M
$1.77M 0.71%
+221,616
New +$1.93M
NRXS icon
27
Neuraxis
NRXS
$85M
$1.69M 0.68%
286,138
– –
AVTX icon
28
Avalo Therapeutics
AVTX
$957M
$1.12M 0.45%
+75,000
New +$1.17M
ANNX icon
29
Annexon
ANNX
$913M
$1.11M 0.45%
+200,000
New +$1.13M
QQQ icon
30
PUT
Invesco QQQ Trust
QQQ
$463B
$1.05M 0.42%
250,000
-200,000
-44% -$122M
AQST icon
31
Aquestive Therapeutics
AQST
$494M
$1.04M 0.42%
+250,000
New +$1.01M
SPY icon
32
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$781B
$959K 0.39%
125,000
-385,000
-75% -$262M
BFRI icon
33
Biofrontera
BFRI
$13.4M
$942K 0.38%
1,163,962
+23,198
+2% +$20K
KURA icon
34
Kura Oncology
KURA
$948M
$813K 0.33%
100,000
– –
RGNT
35
Regentis Biomaterials
RGNT
$14M
$768K 0.31%
251,510
– –
VRDN icon
36
PUT
Viridian Therapeutics
VRDN
$2.05B
$52.7K 0.02%
+263,600
New +$7.83M
AVXL icon
37
PUT
Anavex Life Sciences
AVXL
$224M
– –
-1,168,600
Closed -$1.88M
CYTK icon
38
Cytokinetics
CYTK
$10.7B
– –
-195,045
Closed -$12.4M
OCUL icon
39
Ocular Therapeutix
OCUL
$1.91B
– –
-400,000
Closed -$4.86M
OEF icon
40
PUT
iShares S&P 100 ETF
OEF
$20B
– –
-200,000
Closed -$1.11M
QURE icon
41
CALL
uniQure
QURE
$2.73B
– –
-100,000
Closed -$95K
REPL icon
42
Replimune Group
REPL
$882M
– –
-1,410,497
Closed -$10.8M
TRVI icon
43
Trevi Therapeutics
TRVI
$2.38B
– –
-100,000
Closed -$1.25M
VKTX icon
44
CALL
Viking Therapeutics
VKTX
$4.22B
– –
-100,000
Closed -$2K
VSTM icon
45
CALL
Verastem
VSTM
$505M
– –
-268,600
Closed -$160K
XNTK icon
46
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.09B
– –
-1,937,600
Closed -$1.35M
AVBP icon
47
CALL
ArriVent BioPharma
AVBP
$1.31B
– –
-107,900
Closed -$540K
AVBP icon
48
ArriVent BioPharma
AVBP
$1.31B
– –
-215,871
Closed -$4.88M
GUTS icon
49
Fractyl Health
GUTS
$124M
– –
-385,731
Closed -$849K
ATYR
50
aTyr Pharma
ATYR
$47.7M
– –
-1,039,080
Closed -$13.6M
1
2

Similar funds

FGG
Financial Guidance Group Palm Harbor, Florida $249M AUM 17.15% 1-Year Est. Return
TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
DFG
Dupree Financial Group Lexington, Kentucky $248M AUM 26.52% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return

Rosalind Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Rosalind Advisors held 50 positions worth $249M, down 13% from $285M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Rosalind Advisors withdrew a net $380M in Q1 2026, closing 14 positions and reducing 11 holdings. Its most notable exit was aTyr Pharma, an estimated $13.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier.

Against the trend, Rosalind Advisors opened a new position in Vaxcyte worth $16.9M.

  • Rosalind Advisors's largest Q1 2026 buy was Vaxcyte: 290,000 shares worth $16.9M.
  • Rosalind Advisors added most to Xeris Biopharma Holdings in Q1 2026, an estimated $7.43M increase.
  • Rosalind Advisors's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $11.3M.
  • Rosalind Advisors fully exited aTyr Pharma in Q1 2026, selling an estimated $13.6M.
  • Rosalind Advisors's ten largest holdings make up 66% of its $249M portfolio in Q1 2026.
  • Rosalind Advisors opened 11 new positions and closed 14 in Q1 2026.
  • Rosalind Advisors's portfolio value fell 13% quarter-over-quarter to $249M.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.